Table 1.
Characteristics of patients and tumors at the onset of radiotherapy
| q1w cisplatin (N=165) | q3w cisplatin (N=97) | Test | |
|---|---|---|---|
| Age at treatment initiation (years) | |||
| Median (range) | 58.5 (33.6–79.7) | 54.4 (19.4–70.7) | P<0.001 |
| Sex | |||
| Male | 144 (87.3%) | 83 (85.6%) | P=0.695 |
| Performance status | |||
| 0 | 59 (47.6%) | 35 (47.3%) | P=0.424 |
| 1 | 54 (43.5%) | 33 (44.6%) | |
| 2 | 11 (8.9%) | 4 (5.4%) | |
| 3 | – | 1 (1.4%) | |
| 4 | – | 1 (1.4%) | |
| Unknown | 41 | 23 | |
| Consumptions | |||
| Alcohol | 124/155 (80%) | 65/95 (68.4%) | P=0.039 |
| Tobacco | 144/159 (90.6%) | 83/95 (87.4%) | P=0.424 |
| History of head and neck cancer | |||
| 12 (7.3%) | 2 (2.1%) | P=0.089 | |
| Weight before treatment (kg) | |||
| Median (range) | 65 (39–105) | 71 (37.5–140) | P=0.021 |
| Clearance of creatinine before treatment (mL/min) | |||
| Median (range) | 91 (39–358) | 104 (46–248) | P=0.003 |
| Localization of tumor | |||
| Oral cavity | 24 (14.6%) | 13 (13.4%) | P=0.862 |
| Oropharynx | 81 (49.4%) | 44 (45.4%) | |
| Hypopharynx | 27 (16.5%) | 17 (17.5%) | |
| Larynx | 29 (17.7%) | 22 (22.7%) | |
| Others | 3 (1.8%) | 1 (1%) | |
| Unknown | 1 | – | |
| Stage of the disease | |||
| I | 4 (2.4%) | – | P=0.002 |
| II | 11 (6.7%) | 7 (7.3%) | |
| III | 50 (30.3%) | 12 (12.5%) | |
| IVa and IVb | 100 (60.6%) | 77 (80.2%) | |
| Unknown | – | 1 | |
| Type of chemoradiation | |||
| Exclusive | 42 (25.5%) | 36 (37.1%) | P=0.046 |
| Adjuvant | 123 (74.5%) | 61 (62.9%) | |
| Prior neoadjuvant chemotherapy | |||
| Yes | 56 (33.9%) | 44 (45.8%) | P=0.057 |
| No | 109 (66.1%) | 52 (54.2%) | |
| Unknown | – | 1 | |
Abbreviations: q1w, once weekly; q3w, every 3 weeks.